+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thyroid Cancer Drugs Market by Cancer Type (Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hürthle Cell Carcinoma), Treatment Modality (Chemotherapy, Immunotherapy, Radioiodine Therapy), Drug Type, Mode Of Administration, End User - Global Forecast 2025-2030- Product Image
Thyroid Cancer Drugs Market by Cancer Type (Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hürthle Cell Carcinoma), Treatment Modality (Chemotherapy, Immunotherapy, Radioiodine Therapy), Drug Type, Mode Of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Thyroid Cancer Drugs Market by Cancer Type (Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hürthle Cell Carcinoma), Treatment Modality (Chemotherapy, Immunotherapy, Radioiodine Therapy), Drug Type, Mode Of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5460329
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The thyroid cancer drugs market is evolving quickly as advanced therapies, precision diagnostics, and new regulatory dynamics reshape how care is delivered worldwide. Senior leaders must understand this shifting landscape to align R&D, sourcing, and go-to-market strategies with emerging clinical and commercial realities.

Thyroid Cancer Drugs Market Snapshot

The thyroid cancer drugs market grew from USD 890.96 million in 2024 to USD 994.83 million in 2025. Fueled by innovation and therapeutic expansion, it is expected to advance at a CAGR of 11.12% through 2030, delivering a projected value of USD 1.67 billion. Growth reflects greater adoption of precision medicine, increased awareness, and ongoing pipeline investments across established and emerging regional markets.

Scope & Segmentation

  • Cancer Types: Anaplastic thyroid cancer, follicular thyroid cancer, Hürthle cell carcinoma, medullary thyroid cancer, and papillary thyroid cancer. Each subtype presents distinct molecular profiles that drive targeted therapy adoption and influence clinical development.
  • Treatment Modalities: Chemotherapy, immunotherapy, radioiodine therapy, surgery, targeted multikinase therapy, and thyroid stimulating hormone suppression therapy. The blend of traditional and modern interventions points to increasing clinical complexity.
  • Drug Types: Chemotherapy agents, hormone therapy drugs, immunotherapy drugs, and targeted therapy drugs make up the portfolio, reflecting varying mechanisms in patient management.
  • Mode of Administration: Injectables, including pre-filled syringes and vials, as well as oral forms such as capsules and tablets, cater to both clinical settings and homecare environments.
  • End Users: Hospitals, oncology clinics, homecare settings, and research organizations each follow specific protocols and play direct roles in procurement and adoption.
  • Geographic Regions: Americas, Europe, Middle East & Africa, Asia-Pacific. Regional variations shape regulatory, reimbursement, and distribution strategies.
  • Key Technologies: Precision medicine, molecular diagnostics, targeted multikinase inhibitors, artificial intelligence in imaging and trial design deliver highly individualized care models.

Key Takeaways for Senior Decision-Makers

  • Precision medicine continues to disrupt traditional treatment algorithms, requiring companies to pivot R&D toward biomarker-driven approaches.
  • Multi-regional regulatory and reimbursement models necessitate tailored market access strategies that combine localized evidence generation with strategic partnerships.
  • Integrating artificial intelligence in diagnostics and treatment decisions enables more agile trial designs and personalized care pathways.
  • Diversifying product portfolios between targeted, immunologic, and traditional agents is becoming essential to address unmet needs across aggressive histologies.
  • Collaborations among leading pharmaceutical and biotech firms—combined with investments in companion diagnostics—are accelerating innovation and market entry.
  • Evolving end-user segments, including a rise in oncology clinic and homecare demand, influence formulation strategy and distribution channels.

Tariff Impact on Thyroid Cancer Drug Supply Chains

From 2025, new U.S. tariff regulations increase the cost of sourcing active pharmaceutical ingredients, excipients, and essential manufacturing equipment. These changes drive higher R&D and procurement spend, prompting stakeholders to diversify sourcing by expanding domestic production and entering collaborative supplier agreements. Monitoring ongoing tariff changes and proactively adjusting contracts is crucial for cost management and ensuring steady product access.

Methodology & Data Sources

This analysis uses a rigorous, multisource approach—primarily interviews with oncology, pharma, and health policy experts—complemented by peer-reviewed literature, clinical trial registries, and regulatory filings. Internal peer review and expert validation ensure accuracy and robust trend assessment.

Why This Report Matters

  • Enables evidence-based decisions on R&D investment, market entry, and portfolio prioritization by mapping major trends in the thyroid cancer drugs market.
  • Provides actionable insights for managing volatility in supply chain costs and optimizing strategy for market segmentation, access, and reimbursement.

Conclusion

The thyroid cancer drugs market is on a trajectory defined by innovation, differentiation across settings and regions, and intensifying R&D focus. Understanding these dynamics supports sustainable competitive positioning for stakeholders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of highly selective RET kinase inhibitors improving patient-specific therapy
5.2. Integration of liquid biopsy genomic profiling in early detection and treatment monitoring for thyroid cancer
5.3. Approval and market uptake of second-generation multikinase inhibitors for radioiodine refractory thyroid carcinoma
5.4. Development of combination regimens pairing BRAF inhibitors with immunotherapy to overcome resistance in thyroid cancer
5.5. Expansion of patient access programs driving uptake of costly targeted therapies in emerging markets for thyroid cancer treatment
5.6. Advances in CAR T cell therapies targeting novel antigens in anaplastic thyroid carcinoma management
5.7. Regulatory approvals of peptide receptor radionuclide therapy for advanced medullary thyroid carcinoma patients
5.8. Adoption of real-world evidence studies informing efficacy and safety of new thyroid cancer treatment modalities
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Thyroid Cancer Drugs Market, by Cancer Type
8.1. Introduction
8.2. Anaplastic Thyroid Cancer (ATC)
8.3. Follicular Thyroid Cancer (FTC)
8.4. Hürthle Cell Carcinoma
8.5. Medullary Thyroid Cancer (MTC)
8.6. Papillary Thyroid Cancer (PTC)
9. Thyroid Cancer Drugs Market, by Treatment Modality
9.1. Introduction
9.2. Chemotherapy
9.3. Immunotherapy
9.4. Radioiodine Therapy
9.5. Surgery
9.6. Targeted Multikinase Therapy
9.7. Thyroid Stimulating Hormone (TSH) Suppression Therapy
10. Thyroid Cancer Drugs Market, by Drug Type
10.1. Introduction
10.2. Chemotherapy Agents
10.3. Hormone Therapy Drugs
10.4. Immunotherapy Drugs
10.5. Targeted Therapy Drugs
11. Thyroid Cancer Drugs Market, by Mode Of Administration
11.1. Introduction
11.2. Injectable
11.2.1. Pre-Filled Syringes
11.2.2. Vials
11.3. Oral
11.3.1. Capsules
11.3.2. Tablets
12. Thyroid Cancer Drugs Market, by End User
12.1. Introduction
12.2. Homecare Settings
12.3. Hospitals
12.4. Oncology Clinics
12.5. Research Organizations
13. Americas Thyroid Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Thyroid Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Thyroid Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eisai Co., Ltd.
16.3.2. Exelixis, Inc.
16.3.3. Bayer AG
16.3.4. AstraZeneca PLC
16.3.5. Blueprint Medicines Corporation
16.3.6. Eli Lilly and Company
16.3.7. Merck & Co., Inc.
16.3.8. Merck KGaA
16.3.9. Novartis AG
16.3.10. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THYROID CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. THYROID CANCER DRUGS MARKET: RESEARCHAI
FIGURE 26. THYROID CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. THYROID CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. THYROID CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HÜRTHLE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HÜRTHLE CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 106. CANADA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 107. CANADA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 108. CANADA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 109. CANADA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 110. CANADA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 111. CANADA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. CANADA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 114. CANADA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 115. CANADA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 116. CANADA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 117. CANADA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 122. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 123. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 130. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 131. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 192. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 193. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 194. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 195. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 196. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 197. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 202. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 203. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 206. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 207. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 208. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 209. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 210. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 211. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 214. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 215. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 216. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 217. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. ITALY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 234. ITALY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 235. ITALY THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 236. ITALY THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 237. ITALY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 238. ITALY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 239. ITALY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. ITALY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. ITALY THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 242. ITALY THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 243. ITALY THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 244. ITALY THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 245. ITALY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ITALY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 248. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 249. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 250. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 251. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 252. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 253. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 256. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 257. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 258. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 259. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 284. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 286. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 298. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 299. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 300. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 304. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 305. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 306. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 307. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 308. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 309. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 312. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 313. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 314. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 315. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 318. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 319. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 320. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 321. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 322. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 323. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 324. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 325. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 326. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 327. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 328. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 329. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 330. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 331. QATAR THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 332. QATAR THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 333. QATAR THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 334. QATAR THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 335. QATAR THYROID CANCER DRUGS MARKET SIZE, BY D

Samples

Loading
LOADING...

Companies Mentioned

  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Bayer AG
  • AstraZeneca PLC
  • Blueprint Medicines Corporation
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 994.83 Million
Forecasted Market Value ( USD ) by 2030 $ 1670 Million
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Follicular Thyroid Cancer Drugs - Global Strategic Business Report - Product Image

Follicular Thyroid Cancer Drugs - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy Agents, Immunotherapy, Monoclonal Antibodies), Route Of Administration (Intravenous, Oral, Subcutaneous), Cancer Type, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy Agents, Immunotherapy, Monoclonal Antibodies), Route Of Administration (Intravenous, Oral, Subcutaneous), Cancer Type, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review - Product Image

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

  • Report
  • Global
From
Hurthle Cell Carcinoma Treatment Market by Therapy Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Hurthle Cell Carcinoma Treatment Market by Therapy Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 195 Pages
  • Global
From

About the Thyroid Cancer Drugs Market

The Thyroid Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat thyroid cancer. These drugs are used to reduce the size of tumors, reduce the risk of recurrence, and improve the quality of life for those affected by the disease. Commonly used drugs include radioactive iodine, tyrosine kinase inhibitors, and monoclonal antibodies. The market is highly competitive, with many companies vying for a share of the market. Major players include Pfizer, Novartis, Merck, and Bristol-Myers Squibb. These companies are constantly researching and developing new drugs to improve the treatment of thyroid cancer. Additionally, many smaller companies are also involved in the market, offering generic versions of existing drugs or developing new treatments. Overall, the Thyroid Cancer Drugs market is an important part of the pharmaceutical industry, providing treatments that can improve the quality of life for those affected by the disease. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.